Type III TGF-β receptor downregulation generates an immunotolerant tumor microenvironment. - Wikidata - wikimedia - TriplyDB

Type III TGF-β receptor downregulation generates an immunotolerant tumor microenvironment.

Type III TGF-β receptor downregulation generates an immunotolerant tumor microenvironment.

http://www.wikidata.org/entity/Q37123849

about

Immune evasion pathways and the design of dendritic cell-based cancer vaccines Pathological mobilization and activities of dendritic cells in tumor-bearing hosts: challenges and opportunities for immunotherapy of cancer Heparan sulfate signaling in cancer Early Carcinogenesis Involves the Establishment of Immune Privilege via Intrinsic and Extrinsic Regulation of Indoleamine 2,3-dioxygenase-1: Translational Implications in Cancer Immunotherapy.Stromal heparan sulfate differentiates neuroblasts to suppress neuroblastoma growth.Chitosan-based thermoreversible hydrogel as an in vitro tumor microenvironment for testing breast cancer therapies.Role of TGF-β receptor III localization in polarity and breast cancer progression Ectodomain shedding of TβRIII is required for TβRIII-mediated suppression of TGF-β signaling and breast cancer migration and invasion.Transforming growth factor β-mediated suppression of antitumor T cells requires FoxP1 transcription factor expression The balance of cell surface and soluble type III TGF-β receptor regulates BMP signaling in normal and cancerous mammary epithelial cells.Development and validation of a novel platform-independent metastasis signature in human breast cancer.A multicenter phase I dose escalation trial to evaluate safety and tolerability of intra-arterial temozolomide for patients with advanced extremity melanoma using normothermic isolated limb infusion.Fibulin-3 is a novel TGF-β pathway inhibitor in the breast cancer microenvironment.TβRIII Expression in Human Breast Cancer Stroma and the Role of Soluble TβRIII in Breast Cancer Associated Fibroblasts.Harnessing the immune system for the treatment of breast cancer.Immunotherapy following regional chemotherapy treatment of advanced extremity melanoma Isolated limb infusion as a model to test new agents to treat metastatic melanoma.TGFβ: A player on multiple fronts in the tumor microenvironment.Proteolytic control of TGF-β co-receptor activity by BMP-1/tolloid-like proteases revealed by quantitative iTRAQ proteomics.Matters of context guide future research in TGFβ superfamily signaling.Immunogenic, cellular, and angiogenic drivers of tumor dormancy--a melanoma view.Melanoma-Derived Wnt5a Promotes Local Dendritic-Cell Expression of IDO and Immunotolerance: Opportunities for Pharmacologic Enhancement of Immunotherapy Loss of GDF10/BMP3b as a prognostic marker collaborates with TGFBR3 to enhance chemotherapy resistance and epithelial-mesenchymal transition in oral squamous cell carcinoma.Heparin-binding epidermal growth factor-like growth factor promotes neuroblastoma differentiation.Dichotomous roles of TGF-β in human cancer.A 16 Yin Yang gene expression ratio signature for ER+/node- breast cancer.Characterization of type III TGF-β receptor expression in invasive breast carcinomas: a potential new marker and target for triple negative breast cancer.Surface Expression of TGFβ Docking Receptor GARP Promotes Oncogenesis and Immune Tolerance in Breast Cancer.Relationship of SOCS3 and TGF-β with IDO expression in early pregnancy chorionic villi and decidua.Notch1 signaling in melanoma cells promoted tumor-induced immunosuppression via upregulation of TGF-β1.Dually modified transmembrane proteoglycans in development and disease.Translational control in the tumor microenvironment promotes lung metastasis: Phosphorylation of eIF4E in neutrophils.Paracrine Wnt5a-β-Catenin Signaling Triggers a Metabolic Program that Drives Dendritic Cell Tolerization.Targeting the TGFβ pathway with galunisertib, a TGFβRI small molecule inhibitor, promotes anti-tumor immunity leading to durable, complete responses, as monotherapy and in combination with checkpoint blockade.Heparan Sulfate and Heparan Sulfate Proteoglycans in Cancer Initiation and Progression

P2860

Q28076556-F884025D-4A6B-48BC-A1F7-42AE99977489 Q28392626-B0AC6AF5-3C3E-4308-830B-6F52E5F40834 Q28657828-C2FF72BD-63E3-46FC-AC60-CAB2301B854A Q30410002-EC70A36D-607F-47C7-AC6C-84255A86BFF9 Q33808326-67DA553A-E778-42DB-9088-CE6766E5242A Q33894643-7A0C65B1-AD7E-46CF-89D8-8C095EB03F45 Q33975908-3EBFB5AA-8FCE-4E6F-86C2-71ACD4114993 Q34081397-C353D11C-5F5A-4985-A0C2-B7DD372E2538 Q34240499-E5B395A7-F574-4861-8ECB-EDA602805651 Q34346737-B2439136-F78B-4007-90D1-D70397297A31 Q35606889-E19305F5-788E-46C2-BCAC-3CE7BE5628CB Q35731493-2742EF0D-60AE-49C3-9706-0DCC9CB809A3 Q36108833-5BD8EB8C-08ED-4820-8CAC-8A5DDC4DA05B Q36186532-C8833CF1-4ADC-4F64-BE7D-E93CBF308FB8 Q37476039-D94843E3-3C46-4D3C-AC09-5D8B52418CBF Q37509709-3144FBF4-2CEF-48E1-A721-5F96081276DC Q38187595-DF30D742-BC2D-48E1-9BBB-B869483D1412 Q38241602-1007171F-2B75-474F-811C-8D002BE8B06A Q38423146-3D25A9EA-E546-4CA4-98E9-E3C4261D5002 Q38612468-08EB911C-EB52-4C33-9655-CE1085F8C0B2 Q38619615-D79B0CF9-D4AA-4333-960F-B3CFC9053CFF Q38867762-A7D166C0-BCDE-44DC-8B5B-2E14400E23C7 Q38904950-73C6F4D3-2191-439D-9402-84C0D4D6189C Q38973422-50F0C230-5452-4279-8249-9F20082F1F66 Q39027205-212199D6-4A90-4026-B385-DA53362D6A79 Q39124676-12580FF4-95FC-4265-898B-5ABB285FD777 Q42881932-5568BDB3-6DC1-4CA0-A9EE-1620C3A18802 Q47101209-85A9BAE9-BB5D-4C2E-B0F8-469E7BF192D5 Q47104530-009B2395-DE0D-439B-A84C-3627DED02097 Q47169624-620AC203-D900-4EBA-8844-94ACF9F6220B Q47240245-21F3EFA3-B84D-4C67-B9D1-23943E112143 Q49790269-C1DF5EBC-692D-4DFE-A3E2-1FEDCB79B434 Q49990713-DF7E1173-DA17-44FF-B577-F3110044EEA3 Q55491725-5B1CF271-6652-462A-9D5F-5E3303635740 Q58705289-DC29FD96-E92F-410F-B75B-4AE0CA9F8B58

P2860

Type III TGF-β receptor downregulation generates an immunotolerant tumor microenvironment.

http://www.wikidata.org/entity/Q37123849

description

article científic

@ca

article scientifique

@fr

articolo scientifico

@it

artigo científico

@pt

bilimsel makale

@tr

scientific article published on 08 August 2013

@en

vedecký článok

@sk

vetenskaplig artikel

@sv

videnskabelig artikel

@da

vědecký článek

@cs

name

Type III TGF-β receptor downre ...... lerant tumor microenvironment.

@en

Type III TGF-β receptor downre ...... lerant tumor microenvironment.

@nl

type

label

Type III TGF-β receptor downre ...... lerant tumor microenvironment.

@en

Type III TGF-β receptor downre ...... lerant tumor microenvironment.

@nl

prefLabel

Type III TGF-β receptor downre ...... lerant tumor microenvironment.

@en

Type III TGF-β receptor downre ...... lerant tumor microenvironment.

@nl

P1433

Q37123849-9B324346-E94C-4108-A359-1456D33EE344

P1476

Q37123849-300AF005-B0D0-45C9-89E0-64287C0BDC0A

P2093

Q37123849-0223809E-7F1A-46E1-9B3A-B18D67C4FDB8

Q37123849-08235B15-C756-4F94-B02D-8FC25FB6B2AC

Q37123849-12E68611-4EE9-46B7-9416-31B42072D9A5

Q37123849-215D53CD-549C-4B22-B307-0238CE86DD65

Q37123849-23FC99D4-4E09-48F5-991D-6E1B5B3B6937

Q37123849-28D84ADC-4106-4F29-97A9-8A16E173E073

Q37123849-3DA90326-8999-4B78-9EE0-F89544C54BAE

Q37123849-431DEC93-C7FB-4D27-A305-2A82DA4A452F

Q37123849-759C2779-21CF-4C88-89DE-0CC6BA696FE0

Q37123849-7B71D001-250A-4475-9576-7D220C7AFFAE

P2860

Q37123849-0C71C601-B657-4D48-9CB4-54F367A7BE94

Q37123849-0DCBA2AF-1EB3-4541-AA6F-EC5C79F8BE50

Q37123849-0E32589E-C07C-44D0-B0F5-03E27D9145ED

Q37123849-1AB0B87C-1C80-4452-A3F2-F5B7E4808642

Q37123849-1B2452C4-D10A-48C0-8F6C-BB378597D85C

Q37123849-22420950-A2D1-4B17-8B0C-906781CEB743

Q37123849-2D6A4A4E-55AD-4FFF-AA05-422B81764B30

Q37123849-2F5EBCFC-21E9-43DA-8010-DE10E408C787

Q37123849-3B2190C1-AC2C-4031-84F0-D1710490E68A

Q37123849-3C668DE1-02CE-4B76-B4F1-EB7474A8C82A

P304

Q37123849-6D338533-9F7B-4CBA-A8C7-AB56AD60A718

P31

Q37123849-D382AB33-3DB8-4939-AE02-A465ED6EDFE2

P356

Q37123849-01273AC3-B7F7-4D06-9908-BB55CD4DFC42

P407

Q37123849-AB7A8ED7-62D3-421F-A0C5-BAE93A347332

P433

Q37123849-F2192E4F-3C84-4EEB-8A06-2F94B56D466A

P478

Q37123849-17E19223-7D61-4076-9B71-ECE2E152B6ED

P50

Q37123849-781B95B0-BF3C-4EFC-A1DD-2754B4DF5F87

Q37123849-8A7F6F77-5CC3-4DEA-A662-D690689A92D6

Q37123849-8B0A0139-3311-437F-A084-36031C1F20F3

Q37123849-D533DBDB-3B08-4C7E-805F-89266CEFA9F1

P577

Q37123849-F7B74015-862D-4736-8B32-EC6B4508547C

P698

Q37123849-1E9051F7-4051-4D1E-9C36-A0DCD578F5B2

P932

Q37123849-1E5B4FBC-A9E7-440A-B546-6C82EB5242DB

P356

P1433

Journal of Clinical Investigation

P1476

Type III TGF-β receptor downregulation generates an immunotolerant tumor microenvironment

@en

P2093

Alisha Holtzhausen

http://www.w3.org/2001/XMLSchema#string

Alok Tewari

http://www.w3.org/2001/XMLSchema#string

Amanda George

http://www.w3.org/2001/XMLSchema#string

Andrew Nixon

http://www.w3.org/2001/XMLSchema#string

Christi Augustine

http://www.w3.org/2001/XMLSchema#string

Douglas S Tyler

http://www.w3.org/2001/XMLSchema#string

Gerard C Blobe

http://www.w3.org/2001/XMLSchema#string

Katherine S Evans

http://www.w3.org/2001/XMLSchema#string

Leona Ling

http://www.w3.org/2001/XMLSchema#string

Lihong Sun

http://www.w3.org/2001/XMLSchema#string

P2860

NIH Image to ImageJ: 25 years of image analysis

Loss of type III transforming growth factor beta receptor expression increases motility and invasiveness associated with epithelial to mesenchymal transition during pancreatic cancer progression

Betaglycan can act as a dual modulator of TGF-beta access to signaling receptors: mapping of ligand binding and GAG attachment sites

Membrane-anchored and soluble forms of betaglycan, a polymorphic proteoglycan that binds transforming growth factor-beta

Dendritic cells and the control of immunity

Functional roles for the cytoplasmic domain of the type III transforming growth factor beta receptor in regulating transforming growth factor beta signaling

Dendritic cells as a major source of macrophage-derived chemokine/CCL22 in vitro and in vivo

Cancer immunoediting: from immunosurveillance to tumor escape

ONCOMINE: a cancer microarray database and integrated data-mining platform

Cancer despite immunosurveillance: immunoselection and immunosubversion

P304

3925-3940

http://www.w3.org/2001/XMLSchema#string

P31

scholarly article

P356

10.1172/JCI65745

http://www.w3.org/2001/XMLSchema#string

P407

P433

9

http://www.w3.org/2001/XMLSchema#string

P478

123

http://www.w3.org/2001/XMLSchema#string

P50

Georgia Beasley

Herbert Kim Lyerly

Melissa Hector-Greene

P577

2013-08-08T00:00:00Z

http://www.w3.org/2001/XMLSchema#dateTime

P698

23925295

http://www.w3.org/2001/XMLSchema#string

P932

3754240

http://www.w3.org/2001/XMLSchema#string